← Motilal Oswal Mutual Fund

Motilal Oswal Nifty MidSmall Healthcare Index Fund- Direct Plan-Growth

Index/ETF Data as of Apr 2026 Comparing Mar 2026 → Apr 2026
Share: WhatsApp X
Stocks Held
30
Apr 2026
Equity Holdings
₹30.61 Cr
Equity only, excl. debt & cash
Top 5 Weight
39.2%
Moderate
Top 10 Weight
60.7%
High concentration
Changes
30
0 new · 0 exits
Top Sector
Pharmaceuticals & Biotechnology
77.2% of portfolio
📋 What Happened This Month Among existing holdings, Fortis Healthcare Limited saw the biggest increase — now at 8.50% of the portfolio. Lupin Limited was trimmed the most, now at 9.88%. Lupin Limited remains the top holding with Pharmaceuticals & Biotechnology the dominant sector at 77.2%. ↓ Scroll down for full holdings, sector allocation and month-on-month changes in detail.
Sector Shift Industry allocation month-over-month
Feb 2026 Mar 2026
Sector Prev Curr Delta
Pharmaceuticals & Biotechnology 75.2% 78.0% +2.8%
Healthcare Services 23.8% 21.0% -2.8%
Healthcare Equipment & Supplies 0.9% 0.9% 0.0%
Mar 2026 Apr 2026
Sector Prev Curr Delta
Pharmaceuticals & Biotechnology 78.0% 77.2% -0.8%
Healthcare Services 21.0% 21.8% +0.8%
Healthcare Equipment & Supplies 0.9% 1.0% +0.2%
Biggest Add
Fortis Healthcare Limited
+0.63% · now 8.50%
Biggest Trim
Lupin Limited
-0.79% · now 9.88%

What Changed?

Comparing Mar 2026 → Apr 2026

Mar 2026 Apr 2026
↑ 16 Increased ↓ 14 Decreased
#StockSectorMar 2026Apr 2026Change
1
Fortis Healthcare Limited
₹2.60 Cr
Healthcare Services 7.87% 8.50% +0.63%
2
Cohance Lifesciences Limited
₹42.52 L
Pharmaceuticals & Biotechnology 0.93% 1.39% +0.46%
3
Neuland Laboratories Limited
₹69.76 L
Pharmaceuticals & Biotechnology 1.97% 2.28% +0.31%
4
Glenmark Pharmaceuticals Limited
₹1.96 Cr
Pharmaceuticals & Biotechnology 6.10% 6.40% +0.30%
5
Laurus Labs Limited
₹2.32 Cr
Pharmaceuticals & Biotechnology 7.34% 7.57% +0.23%
6
Wockhardt Limited
₹62.31 L
Pharmaceuticals & Biotechnology 1.85% 2.04% +0.19%
7
Mankind Pharma Limited
₹1.37 Cr
Pharmaceuticals & Biotechnology 4.31% 4.49% +0.18%
8
Poly Medicure Limited
₹31.21 L
Healthcare Equipment & Supplies 0.86% 1.02% +0.16%
9
Piramal Pharma Limited
₹54.24 L
Pharmaceuticals & Biotechnology 1.61% 1.77% +0.16%
10
Syngene International Limited
₹47.97 L
Healthcare Services 1.41% 1.57% +0.16%
#StockSectorMar 2026Apr 2026Change
1
Lupin Limited
₹3.02 Cr
Pharmaceuticals & Biotechnology 10.67% 9.88% -0.79%
2
IPCA Laboratories Limited
₹1.15 Cr
Pharmaceuticals & Biotechnology 4.23% 3.76% -0.47%
3
Biocon Limited
₹1.39 Cr
Pharmaceuticals & Biotechnology 4.90% 4.54% -0.36%
4
Alkem Laboratories Limited
₹1.71 Cr
Pharmaceuticals & Biotechnology 5.89% 5.58% -0.31%
5
JB Chemicals & Pharmaceuticals Limited
₹90.40 L
Pharmaceuticals & Biotechnology 3.21% 2.95% -0.26%
6
Abbott India Limited
₹70.96 L
Pharmaceuticals & Biotechnology 2.57% 2.32% -0.25%
7
Ajanta Pharma Limited
₹64.24 L
Pharmaceuticals & Biotechnology 2.25% 2.10% -0.15%
8
Gland Pharma Limited
₹75.32 L
Pharmaceuticals & Biotechnology 2.57% 2.46% -0.11%
9
Pfizer Limited
₹38.49 L
Pharmaceuticals & Biotechnology 1.36% 1.26% -0.10%
10
GlaxoSmithKline Pharmaceuticals Limited
₹52.24 L
Pharmaceuticals & Biotechnology 1.80% 1.71% -0.09%

Full Portfolio

30 stocks — Apr 2026

# Stock Sector Cap Weight & Value
1
₹3.02 Cr
Pharmaceuticals & Biotechnology
9.88%
2
₹2.60 Cr
Healthcare Services
8.50%
3
₹2.32 Cr
Pharmaceuticals & Biotechnology
7.57%
4
₹2.10 Cr
Pharmaceuticals & Biotechnology
6.87%
5
₹1.96 Cr
Pharmaceuticals & Biotechnology
6.40%
6
₹1.71 Cr
Pharmaceuticals & Biotechnology
5.58%
7
₹1.39 Cr
Pharmaceuticals & Biotechnology
4.54%
8
₹1.37 Cr
Pharmaceuticals & Biotechnology
4.49%
9
₹1.15 Cr
Pharmaceuticals & Biotechnology
3.76%
10
₹95.98 L
Healthcare Services
3.14%
🏆 Top stocks held by Equity funds
See which stocks all active Equity fund managers are buying — ranked by total value invested
🏦 Motilal Oswal Mutual Fund — Portfolio & Holdings
See all funds managed by Motilal Oswal Mutual Fund — conviction stocks, monthly entries & exits

Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.

Found a discrepancy or have feedback? Contact Us — we read every message personally.